2 Top Biotech Stocks Defying the Bear Market
Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis (NASDAQ: EXEL) and Axsome Therapeutics (NASDAQ: AXSM), two mid-cap biotech stocks. There are good reasons these drugmakers crushed the market since early 2022 and could continue doing so moving forward. Let's discuss why Exelixis and Axsome are solid picks for investors.
Source Fool.com
Exelixis Inc. Aktie
21,52 €
0,89 %
Klares Signal: Exelixis Inc. wird ausschließlich zum Kauf empfohlen.
Bei einem Kursziel von 26 € für Exelixis Inc. deutet sich eine Steigerung von über 20% vom aktuellen Kurs von 21.52 € an.
